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AB S T R A CT  
Despite a perpetual increase in the prevalence of benign lymphoepithelial lesion, data on the 
mechanisms governing its pathogenesis are still missing. Thus, we aimed in the present study to evaluate 
whether TLRs could regulate the expression of the pleiotropic pro-inflammatory and tumor-related 
cytokine MIF in BLEL. Using gene expression profiling and protein expression analysis methods, we 
found that TLRs were overexpressed and that their signaling pathways were activated in BLEL. We 
have also confirmed in tissues biopsies, the overexpression of MIF reported previously in plasma of 
BLEL specimen. The analysis of the TLR7/8 impact on the expression of MIF in BLEL primary cells 
showed that when activated, TLR7/8 stimulate mainly BLEL lymphocytes to release MIF but not the 
fibroblast-like cells. No significant change was observed when MIF expression was investigated at the 
transcriptional level 24h post TLR7/8 activation. Taken together, these data suggest that TLR7 and 
TLR8 are activated in BLEL and may induce a cell type-dependent regulation of MIF secretion and 
expression.  
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 Introduction  
Benign lymphoepithelial lesion (BLEL) also 
known as Mikulicz’s disease is a systemic 
inflammatory IgG4-related disease of lacrimal 
and salivary glands which affects both men and 
women, with irreversible consequences such as 
malignant transformation if left untreated. It’s 
characterized by a chronic bilateral lacrimal and 
salivary gland enlargement due to infiltration of 
abundant IgG4 positive plasmacytes into the 
affected BLEL tissues [1-3]. Since its first 
description in 1888, the exact etiology of BLEL 
and the molecular mechanisms underlying its 
pathogenesis remain unknown. Recently, our 
team showed that the pro-inflammatory cytokine 
macrophage migration inhibitory factor (MIF) is 
overexpressed in the plasma of BLEL patients 
[4], however, the causes of this deregulated 
expression remained unclear.  
MIF is a pleiotropic pro-inflammatory cytokine 
implicated in the pathogenesis of several 
inflammatory disorders, autoimmune diseases 
and tumors [5-7]. MIF is synthesized and stored 
in the cytoplasm of many cells [8, 9] and is 
released in response to various stimuli including 
Toll-like receptors (TLRs) engagement with their 
specific ligands [10]. TLRs are involved in several 
inflammatory diseases and their activation has 
been shown to trigger the transcription of genes 
responsible for the synthesis of numerous 
inflammation cytokines [11-13]. Taken together 
with the high level of plasmatic MIF reported, the 
purpose of the present study was to evaluate 
whether TLRs could be the regulators of MIF 
expression in BLEL. 
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 Materials and Methods  
 Microarray Analysis 
Microarray data of orbital cavernous 
hemangioma (CH; control) and BLEL tissue 
biopsies obtained from gene expression omnibus 
database (accession number GSE76497) were 
used to analyze TLRs gene expression between 
the control and BLEL groups. GeneSpring 
software version 14.9 (Agilent Technologies) was 
used for background correction, quantile 
normalization and to summarized the expression 
data. A fold change ≥ 2 and a false discovery rate 
(FDR) < 0.01 were considered to indicate a 
statistically significant difference.  
 Western Blot and Immunohistochemistry 
The immunoblotting was performed with targets 
specific antibodies (Table 1) on total tissue lysates 
and the immunohistochemistry staining 
performed with MIF antibodies (sc-271631; 
Santa Cruz Biotechnology)  on paraffin-
embedded tissue sections from BLEL and CH 
specimens as previously described by Adzavon et 
al. [14]. 
 Cell Culture and Stimulation  
After a signed consent was obtained from all 
patients included in this study, tissues biopsies 
were collected and primary cells were cultured 
from fresh tissue biopsies of three (3) BLEL 
patients. The tissue biopsies were washed with 
PBS (1X), minced in small pieces, seeded in a 
Corning® T25 culture flask and cultured at 37°C 
in presence of 5% CO2 with DMEM/High 
glucose (HyClone®, ThermoScientiﬁc) for 
adherent cells or RPMI-1640 (gibco® by life 
technology™) for suspension cells. The medium 
was supplemented with 10% of Fetal Bovine 
Serum (gibco®, life technology™) and 1% of 
10,000 Units/ml Penicillin and 10,000 µg/ml 
Streptomycin (gibco®, life technology™) and 
was renewed twice a week. The cells were passed 
when 80-90% confluence was reached and cells 
from passage 4 were stimulated with 6µg/ml of 
TLR7/8 agonist resiquimod (R848) for 24h to 
mimic TLR7/8 activation in vitro. 
 Enzyme-linked Immunosorbent Assay 
Cell culture supernatants were collected from 
both R848-stimulated and unstimulated cells and 
MIF was quantified with RayBio human MIF 
ELISA kit (RayBiotech.Inc) as we reported 
previously [14] 
 RT-qPCR 
RNA was extracted from BLEL cells and the 
analysis of MIF and its related receptors genes 
expression was performed as previously reported 
[14]. The primers used are listed in the Table 2. 
 
Table 1: List of Antibodies 
Name Host 
species 
Catalog 
Number 
Provider 
Beta-Actin (OTI1) Mouse TA-09 ZSGB-BIO 
MIF (D-2) Mouse sc-271631 Santa cruz 
biotechnology 
Anti-NF-kB p65 
antibody 
Rabbit ab16502 Abcam 
Phospho-IRF-7 
(Ser471/472) 
 
#5184 CST 
Anti-TLR7 antibody 
[EPR2088(2)] 
Rabbit ab124928 Abcam 
IRDye® 800CW 
Goat anti-mouse 
Goat 926-32210 LI-COR 
IRDye® 800CW 
Goat anti-Rabbit 
Goat 926-32211 LI-COR 
 
Table 2: List of primer used for the RT-qPCR 
Target 
genes 
Forward (5' to 3') Revers (5' to 3') References 
MIF CTCTCCGAGCTCACCCAGCAG CGCGTTCATGTCGTAATAGTT [15] 
CD74 TGACCAGCGCGACCTTATCT GAGCAGGTGCATCACATGGT  [16] 
CXCR4 AGGGGATCAGTATATACACTT TGCCCACAATGCCAGTTAAG [17] 
CXCR2 AGGCACAGTGAAGACATCGG CAGCAGGCTCAGCAGGAATA [18] 
CD44 GTGATGGCACCCGCTATG ACTGTCTTCGTCTGGGATGG [19] 
TLR7 AAACTCCTTGGGGCTAGATG AGGGTGAGGTTCGTGGTGTT [20] 
TLR8 CAGAGCATCAACCAAAGCAA GCTGCCGTAGCCTCAAATAC [21] 
GAPDH ACACCCACTCCTCCACCTTT TAGCCAAATTCGTTGTCATACC [22] 
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 Statistics 
Quantitative data were analyzed using GraphPad 
Prism v.5 (GraphPad Software, Inc., La Jolla, CA,  
USA) and are plotted as the mean ± standard 
error of the mean. Unpaired t-test was the 
statistical test used and p-value less than 0.05 was 
considered to indicate a statistically significant 
difference. 
 Results and Discussion 
 TLRs Signalization Pathways are 
Activated in BLEL 
TLRs have crucial functions in host antimicrobial 
defense, immune cell regulation, and 
inflammatory response [11-13]. In support of this 
concept together with the inflammatory response 
involvement reported in BLEL pathology [23-
25], we analyzed the expression of TLRs gene in 
BLEL tissues. Half of the ten TLRs analyzed by 
microarray were overexpressed compared to the 
control group (CH) as shown in the Figure 1A. 
The results of the mRNA expression were 
confirmed at proteins level by western blot for 
TLR7 (Figure 1B). Next, we analyzed the 
expression of the downstream components of 
TLRs signalization pathways such as p65/ReLA 
NF-kB [26, 27] and IRF-7 [28]. This analysis 
revealed an important expression of the 
p65/ReLA NF-kB and an enhanced 
phosphorylation of the Interferon regulatory 
factor 7 (IRF7), which confirmed that TLRs 
signaling pathways are activated in BLEL (Figure 
1C). 
Figure 1: TLRs signaling pathways are activated in BLEL. (A) TLRs mRNA analyzed by microarray. (B) TLRs 
proteins expression confirmed by western blot. (C) TLR downstream components analyzed by western blot. * P-
value < 0.05; ** P-value <0.01; *** P-value < 0.001; no stars for P-value >0.05  
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Figure 2: Immunostaining of MIF in BLEL and CH tissues biopsies. The figures presented are representative of 
staining performed on 10 CH and 10 BLEL specimen tissue biopsies 
 MIF is Overexpressed in BLEL Tissue 
Biopsies.  
In order to confirm and identify cells that 
produced and released MIF in BLEL, we 
performed an immunostaining with MIF 
antibodies in tissue biopsies. As shown in the 
Figure 2, MIF is highly expressed in the whole 
BLEL tissue with the strongest expression noted 
in infiltrated lymphocytes and epithelial acinar 
cells.    
 TLRs Differently Regulate MIF 
Expression in BLEL Primary Cells 
In this investigation, we focused mainly on 
TLR7/8 pathways given that they were the most 
enriched among the TLRs pathways in BLEL 
(Data not showed). Three (3) BLEL primary cells 
were established for this purpose: two fibroblast-
like cells named BLELp1 and BLELp2 and a 
tissue-derived primary lymphocyte (Figure 3A-
3C). The expression of TLR7/8 was confirmed 
in these primary cells as shown in the Figure 3D. 
To address whether TLRs influence MIF 
expression in BLEL, the established BLEL 
primary cells were stimulated with TLR7/8 
agonist R848 (6µg/ml) for 24h. Under basal 
conditions, MIF concentration in the cell culture 
supernatant varies considerably between the 
different primary cells. In the absence of TLR7 
and TLR8 stimulation, BLEL primary cells 
secreted a low concentration of MIF. Indeed, the 
primary fibroblast cells BLELp1 and BLELp2 
secreted MIF respectively at a concentration of 
4.34ng/ml and 1.2ng/ml while the MIF released 
by the tissue-derived lymphocytes was dosed at 
2.09ng/ml. These results are in accordance with 
the concentration of MIF reported in normal 
physiological conditions in adult population [29].  
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Figure 3: Characteristic of the BLEL primary cells. (A-C) morphological features of the BLEL primary. (D) 
TLR7/8 mRNA expression analyzed by RT-qPCR before and after treatment with R848. * P-value < 0.05; ** P-
value <0.01; *** P-value < 0.001; no stars for P-value >0.05   
  
Following stimulation with R848, MIF was highly 
released (13.11 fold increase of MIF in the culture 
supernatant) by the primary lymphocytes 
(R848+: 27.53 ng/ml vs Control: 2.09 ng/ml) but 
not by the primary fibroblast-like cells BLELp1 
and BLELp2 (Figure 4A), suggesting that the 
ability of the fibroblast-like cells to release MIF 
was abrogated when TLR7 and TLR8 were 
activated and that in BLEL in which TLR7 and 
TLR8 are activated, the lymphocytes would be 
the main source of the release of MIF in plasma. 
The fact that TLR7 and TLR8 activation induced 
the release of MIF in the primary lymphocytes 
but not in the primary fibroblast-like cells is 
suggestive of a cell type-dependent regulation of 
MIF secretion in BLEL; an observation reported 
previously in other cell type [10, 14].  
At the gene level, TLR7/8 activation did not 
influence MIF and its receptors mRNA 
expression (Figure 4B, 4C). This suggests that at 
least in these two primary cells TLR7 and TLR8 
activation do not induce de novo synthesis of 
MIF. Taken together, these data demonstrate a 
differentially regulation of MIF expression by 
TLR7/8 in BLEL and suggested the lymphocytes 
as one of the main source of the circulating MIF 
in plasma. 
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Figure 4:  Influence of TLR7/8 activation on the expression of MIF and its receptors in BLEL primary cells. * P-value 
< 0.05; ** P-value <0.01; *** P-value < 0.001; no stars for P-value >0.05 
 
MIF biological functions mainly relied on 
interaction with its receptors CD74, CD44 and 
CXCR2/4/7 [5, 30-33]. Given that TLR7/8 
activation induced the release of MIF in BLEL 
primary cells, we thought it could also influence 
the expression of MIF-related receptors; 
however, following 24h of exposure to TLR7/8 
agonist R848, no significant change was observed 
(Figure 4B & 4C).  
 Conclusions 
In the present study, we provide evidence that 
TLR7 and TLR8 pathways are activated and 
regulated MIF proteins expression in BLEL, 
however, this influence may differ from one cell 
type to another. In addition, given the pro-
inflammatory properties of MIF, it could be 
conceivable that TLRs play key roles in the 
regulation of the inflammatory response in BLEL.  
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